Seeding competent TDP-43 persists in human patient and mouse muscle
Eileen M. LynchiD, Sara K. Pittman, Jil DawiD, Chiseko IkenagaiD, Sheng CheniD, Dhruva D. DhavaleiD, Meredith E. JackreliD, Yuna M. AyalaiD, Paul T. KotzbaueriD, Cindy V. LyiD, Alan PestronkiD, Thomas E. LloydiD, Conrad Chris WeihliD
Abstract
TAR DNA-binding protein 43 (TDP-43) is an RNA binding protein that accumulates as aggregates in the central nervous system of some neurodegenerative diseases. However, TDP-43 aggregation is also a sensitive and specific pathologic feature found in a family of degenerative muscle diseases termed inclusion body myopathy (IBM). TDP-43 aggregates from ALS and FTD brain lysates may serve as self-templating aggregate seeds in vitro and in vivo, supporting a prion-like spread from cell to cell. Whether a similar process occurs in IBM patient muscle is not clear. We developed a mouse model of inducible, muscle-specific cytoplasmic localized TDP-43. These mice develop muscle weakness with robust accumulation of insoluble and phosphorylated sarcoplasmic TDP-43, leading to eosinophilic inclusions, altered proteostasis and changes in TDP-43-related RNA processing that resolve with the removal of doxycycline. Skeletal muscle lysates from these mice also have seeding competent TDP-43, as determined by a FRET-based biosensor, that persists for weeks upon resolution of TDP-43 aggregate pathology. Human muscle biopsies with TDP-43 pathology also contain TDP-43 aggregate seeds. Using lysates from muscle biopsies of patients with IBM, IMNM and ALS we found that TDP-43 seeding capacity was specific to IBM. Surprisingly, TDP-43 seeding capacity anti-correlated with TDP-43 aggregate and vacuole abundance. These data support that TDP-43 aggregate seeds are present in IBM skeletal muscle and represent a unique TDP-43 pathogenic species not previously appreciated in human muscle disease. SummaryTDP-43 aggregate seeds persist in mouse and human skeletal muscle independent of large TDP-43 inclusions.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 25
- FWCI
- 6.09
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Skeletal muscle TDP-43 aggregation drives progressive motor dysfunction and neurodegeneration with potential for functional recovery after clearance
Shuzhao Zhuang, Nadia Hafizi Rastabi, … Aaron Paul Russell·bioRxiv·Jul 20, 2025
- Corticospinal propagation of full-length TDP-43 toxicity drives brain-to-muscle pathology
Jacopo Marongiu, V. Crippa, … Anna Rosa Carta·bioRxiv·Mar 30, 2026
- Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis
K. A. Britson, J. P. Ling, … T. E. Lloyd·bioRxiv·Apr 9, 2021
- Cell environment shapes TDP-43 function: implications in neuronal and muscle disease
Urša Šušnjar, Neva Škrabar, … Emanuele Buratti·Communications BiologyPeer-reviewed·Apr 5, 2022
- TDP-43 is required to build and maintain sarcomeres
Haileigh Gay, Theodore E. Ewachiw, … Bradley B. Olwin·bioRxiv·Jun 16, 2026
- TDP-43 pathology is linked to motor neuron loss and is independent of stress granules in vivo
Alicia F. Dubinski, Ala Ferdi, … Christine Vande Velde·bioRxiv·Apr 14, 2026